Losartan Potassium Tablets Recalled Due to Impurity Detection
Golden State Medical Supply Inc. is recalling Losartan Potassium 50 mg tablets because an impurity was detected in the active ingredient.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The agency classified this as an FDA Class II recall. Per the rubric, FDA Class II recalls are assigned a severity score of 4 (Severe), particularly when involving significant potential hazards like nitrosamine impurities in pharmaceuticals.
Plain-English summary
Golden State Medical Supply Inc. is recalling Losartan Potassium, 50 mg tablets, 30 count bottles (NDC 60429-317-30). The recall involves 4,037 bottles, containing a total of 121,110 tablets. The specific lot number is GS017479, with an expiration date of 01/2020.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations. Specifically, an impurity identified as N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) was detected in the active pharmaceutical ingredient (API) used to manufacture the finished products.
The affected products were distributed to one US government account nationwide. No foreign accounts were involved. Consumers and healthcare providers should check their inventory for this specific NDC, lot number, and expiration date. If found, the product should be returned to the supplier or disposed of according to local regulations.
The recalled product
- Product
- Losartan Potassium, 50 mg tablets, 30 count bottle, NDC 60429-317-30
- Manufacturer
- Golden State Medical Supply Inc.
- Category
- Drug — Prescription Medication
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot #: GS017479
- Expiration 01/2020
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 4 recalled by Golden State Medical Supply Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 4 products in this recall →Related recalls
Same manufacturer · Golden State Medical Supply Inc.
See all →- SevereGolden State Medical Supply Recalls Prasugrel Tablets for Failed Dissolution
FDA (Drugs) · 2026-09-09
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- ModerateNiacin extended-release tablets failed dissolution testing at 24 hours
FDA (Drugs) · 2026-06-17
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- ModeratePrimidone Tablets Recalled Due to API Cross-Contamination
FDA (Drugs) · 2026-05-27
Same hazard · impurity
See all →- ModerateAjanta Pharma Recalls Fluphenazine Hydrochloride Tablets Due to Impurity Failure
FDA (Drugs) · 2026-09-16
- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
Similar recalls
- SevereLosartan Potassium Tablets Recalled Due to Impurity Presence
FDA (Drugs) · 2019-05-29
- SevereLosartan Potassium Tablets Recalled Due to NBMA Impurity Detection
FDA (Drugs) · 2020-04-22
- SevereTeva Recalls Losartan Potassium Tablets Due to Impurity Detection
FDA (Drugs) · 2019-07-17
- SevereMacleods Pharma Recalls Losartan Potassium Tablets Due to Impurity
FDA (Drugs) · 2019-07-17
- SevereMajor Pharmaceuticals Recalls Losartan Potassium Tablets Due to Impurity
FDA (Drugs) · 2019-07-17
- SevereAvKARE Recalls Losartan Potassium Tablets Due to Impurity
FDA (Drugs) · 2019-05-08